N/A N=92 Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study
Ventricular Septal Defects
Primary: Primary Effectiveness End Point: Technical Success — 75 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=519 A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Fibromyalgia · Myofascial Pain Syndromes · Muscular Diseases
Primary: Proportion of Patients With ≥30% Pain Improvement — 58; 75 Participants
N/A N=150 Peer Intervention to Link Overdose Survivors to Treatment (PILOT)
Opioid Overdose
Primary: Number of Self-reported Overdose Risk Behaviors at 180 Days (6 Months) After Index ED Admission — 4.5; 5.6 units on a scale — p=0.399
Phase 2 N=35 A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia
Primary: Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12. — -3.10…
N/A N=18 A Multicomponent Intervention to Address Gender-based Violence in HIV
Acceptability of Health Care · HIV Primary Infection
Primary: Acceptability Quantitative — 3.5 score on a scale
N/A N=23,659 E-health Implementation (Iowa)
Substance Use Disorders
Primary: Reach: As Assessed by the Mean Number of Clinics With Participants Who Download the A-CHESS App — 0.039; 0.171 Mean number of clinics
N/A N=20 Intraoral Imaging at Clinical Crown Lengthening
Dental Caries of Root Surface · Surgery
Primary: Pocket Depth — 2.7; 2.4 mm — p=<0.05
N/A N=37 A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Kidney Transplant Failure and Rejection
Primary: Evaluation of Graft Survival in Subjects Who Have Undergone Kidney Transplantation After Imlifidase Administration. — 91 percentage
N/A N=977 Facilitating Communication Study
Chronic Disease · Neoplasm Metastasis · Lung Neoplasm
Primary: Depression Symptoms, Family (HADS-D) — 6.4; 6.5; 6.3; 5.9 score on a scale — p=0.688
Phase 2 N=73 Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
Food Allergy · Peanut Allergy
Primary: Percentage of Children That Tolerate the Full Challenge — 100; 21 percentage of participants
Phase 2 N=13 Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
C3G · IC-MPGN · Renal Transplant
Primary: Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12 — 50.0; 33.3 Percentage of participants
Phase 2 N=60 A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Primary: ORR — 13 Participants
N/A N=302 Communication and Coping for Mothers of Adolescents With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Glycemic Control (A1C) — 8.4; 8.5 Percentage of glycated hemoglobin
N/A N=46 Continuous Diffusion of Oxygen Treatment for Incision Wounds
Surgical Wound · Breast Surgery · Mammoplasty
Primary: Wound Size at 4 Weeks — 1.5; 2.75; 0.15 cm^2
N/A N=65 Intra-articular Polyacrylamide Hydrogel in Gonarthrosis
Osteoarthritis
Primary: Change in the Total WOMAC Score (WOMAC-T) — 649.80; 1091.70; 767.47; 293.60 score on a scale — p=0.004